Pharma

Eisai’s Insomnia drug DAYVIGO approved for Use in China

Eisai Co., Ltd. DAYVIGO® (lemborexant) has been approved in China, where it’s sold as “达卫可®.” The drug will likely launch in the second quarter of fiscal year 2025. It’s for adults who have trouble falling asleep or staying asleep. DAYVIGO is a dual orexin receptor antagonist. It targets the brain's sleep-wake system by binding to orexin receptors OX1R and OX2R. It has a stronger effect on OX2R. This mechanism helps you fall asleep and stay asleep. It does this by reducing the drive for both REM and non-REM sleep. The approval comes after global Phase 3 trials (SUNRISE 1 and 2) with about 2,000 adults. It also includes a Phase 3 study specific to China. Findings demonstrated the drug’s effectiveness in addressing insomnia symptoms. Also Read: Lantern Pharma completes LP-300…